{"disease":{"id":"braf-v600e-mutant-colorectal-cancer","name":"braf v600e mutant colorectal cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02928224","title":"Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":702,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT07007689","title":"A Multi-omics Study of BRAF V600E Mutant Colorectal Cancer","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT03693170","title":"Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":95,"lead_sponsor_name":"Pierre Fabre Medicament","has_results":true}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}